Weight-loss drugs linked to rare eye condition in massive data review

A massive new review of medical data indicates that patients taking popular weight-loss and diabetes medications may face a higher risk of developing a rare but serious eye condition. The research, published in Neurology, found that people using semaglutide experience sudden vision loss at a higher rate than those using other treatments. The results offer a detailed look at the potential side effects associated with this rapidly growing class of drugs.

Nonarteritic anterior ischemic optic neuropathy is a condition in which blood flow to the optic nerve is restricted. This vital nerve connects the eye to the brain, and a lack of blood flow causes the tissue to swell. The swelling results in sudden, painless vision loss, typically in just one eye. The condition frequently leads to permanent visual damage, making it the leading cause of acute optic nerve injury in older adults.

Risk factors for this type of nerve damage include high blood pressure, type 2 diabetes, and sleep apnea. Certain anatomical features, such as having a crowded optic nerve head in the back of the eye, can also increase a person’s vulnerability. Because these risk factors overlap heavily with metabolic diseases, isolating the true cause of the neuropathy in patients is often difficult.

Medications like semaglutide belong to a class of drugs known as glucagon-like peptide-1 receptor agonists. These drugs mimic a naturally occurring hormone in the body to delay stomach emptying and reduce a person’s appetite. They also help the pancreas release insulin in response to meals, which controls blood sugar levels. Doctors prescribe them widely to treat type 2 diabetes and clinical obesity.

Millions of patients now take these medications globally, making the identification of rare side effects a public health priority. Recent observational studies looking at these medications and eye health have produced conflicting results. Some individual studies suggested the drugs increased the risk of optic neuropathy. Other analyses found no association or even hinted at a protective effect against vision loss.

Free daily newsletter

To synthesize the available data and resolve these contradictions, a team of researchers conducted a comprehensive meta-analysis. Thanansayan Dhivagaran, Fahad Butt, and Luckshann Arunasalam of the University of Western Ontario led the study. They collaborated with Edward Margolin and other colleagues from the University of Toronto.

The researchers systematically searched medical databases for observational studies published up to April 2025. They specifically looked for studies comparing the risk of optic neuropathy between patients using the medications and those using alternative treatments. The team established strict criteria to avoid counting the same patients multiple times across overlapping data registries.

They pooled data from five main studies to form a massive sample of 1,593,554 patients. This group included 682,456 patients using semaglutide and 911,098 using other drugs. The team used specialized Bayesian statistical models to calculate the relative risk and the overall incidence of the eye condition. These models are particularly useful for analyzing extremely rare medical events.

The primary analysis revealed that semaglutide use was associated with a 152 percent higher risk of developing the optic neuropathy compared to the use of alternative medications. The statistical models showed a 99.9 percent probability that the true relative risk was greater than one. Despite this relative increase, the absolute number of cases remained very low in the population.

The researchers calculated an overall incidence of 118 cases per 100,000 semaglutide users. Across all medications in this class, including dulaglutide and exenatide, the incidence was 85 cases per 100,000 users. These numbers translate to less than a fraction of a percent of all patients taking the drugs.

The team then looked specifically at patients with diabetes to see if the underlying condition influenced the risk. They analyzed data from five studies covering roughly 1.59 million individuals. This massive subset was split between semaglutide users and those managing their diabetes with other treatments.

Among patients with diabetes, semaglutide users had a 141 percent higher risk of developing the eye condition compared to non-users. The absolute risk in this specific group was estimated at 125 cases per 100,000 semaglutide users. The statistical evidence supporting this association remained extremely strong across multiple sensitivity analyses.

Next, the researchers examined the risk among patients prescribed semaglutide specifically for obesity. They pooled data from two studies that included a large sample of 116,613 patients. This group consisted of 58,254 semaglutide users and 58,359 individuals taking alternative weight-loss medications.

In the obesity subgroup, semaglutide was associated with a 77 percent higher risk of the optic neuropathy compared to the alternative treatments. The incidence rate in this group was notably higher at 712 cases per 100,000 semaglutide users. The researchers noted that the statistical certainty for this specific subgroup was moderate rather than strong.

To provide more context, the researchers evaluated how semaglutide compared directly to other specific classes of drugs. They analyzed data comparing semaglutide to SGLT2 inhibitors, which are another common type of diabetes medication. This comparison involved a massive sample of nearly 948,000 patients.

Patients taking semaglutide had roughly twice the risk of developing the vision condition compared to those taking SGLT2 inhibitors. The team also compared semaglutide to other drugs within the same class in a sample of about 865,000 patients. When compared to users of other similar medications, semaglutide users faced a 61 percent higher risk.

The exact biological reason for this association remains unknown. One hypothesis suggests that the blood pressure-lowering effects of the medications might reduce blood flow to the optic nerve head. Animal and human studies show that these drugs interact with bodily systems regulating sodium absorption and blood pressure. In susceptible individuals, this chronic reduction in local blood pressure could trigger the neuropathy.

Weight loss itself might also indirectly lead to lower blood pressure, compounding the effect. Patients experiencing rapid weight loss may require adjustments to their existing blood pressure medications to prevent sudden drops. If these adjustments are not made, the resulting low blood pressure might leave the optic nerve vulnerable to injury.

Because this meta-analysis relied exclusively on observational data, the results cannot prove that semaglutide directly causes the eye condition. Patients prescribed these newer medications often have more severe or poorly controlled metabolic diseases. Advanced diabetes and obesity are themselves major drivers of vascular damage and nerve problems. This underlying disease severity could be contributing to the higher rates of vision loss in the treatment groups.

The researchers also noted that it takes time for the medications to reach their maximum effect in the body. Cases of vision loss that occur shortly after a patient starts the drug might reflect preexisting vascular risks rather than a side effect of the treatment. Additionally, the studies included in the review mostly featured White populations from the United States, Denmark, and Norway. This demographic limitation restricts how broadly the findings can be applied to other groups.

Health care providers must weigh this rare risk against the well-documented systemic benefits of the medications. Large clinical trials have shown that these drugs reduce the incidence of cardiovascular death, nonfatal heart attacks, and strokes. The medications may even protect against other prevalent eye diseases like diabetic retinopathy and glaucoma. For the vast majority of patients, the broad improvements in metabolic health likely outweigh the low absolute risk of this specific neuropathy.

Future research will need to track visual outcomes in patients over longer periods while strictly controlling for existing vascular risk factors. Prospective trials could help clarify the exact biological mechanisms linking the medications to blood flow changes in the eye. Until more data is available, the authors suggest that doctors discuss potential visual risks when prescribing these medications. Patients initiating therapy should seek prompt ophthalmic evaluation if they experience sudden visual changes.

The study, “Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Systematic Review and Meta-Analysis,” was authored by Thanansayan Dhivagaran, Fahad Butt, Luckshann Arunasalam, Isabel Bae, David Mikhail, Brendan K. Tao, Jim Shenchu Xie, Michael Balas, Marko Popovic, and Edward Margolin.